<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637091</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-2008-0031</org_study_id>
    <nct_id>NCT00637091</nct_id>
  </id_info>
  <brief_title>Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions</brief_title>
  <official_title>A Phase II Trial of Cetuximab Plus Irinotecan as a 2nd-line Treatment in Patients With Metastatic Colorectal Cancer After Failure to Irinotecan That Express Wild-type KRAS With and Without Detectable EGFR Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the response rate of cetuximab plus irinotecan&#xD;
      every 2 weeks in patients harboring wild-type KRAS with and without detectable&#xD;
      EGFR-expressing metastatic CRC after failure to irinotecan in an exploratory manner.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty patients with positive-EGFR results and 20 patients with negative-EGFR results will be&#xD;
      accrued in this study. All patients should have wild-type KRAS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, overall survival</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>EGFR expression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients' accrual will be adjusted by EGFR expression (positive vs. negative)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab, irinotecan</intervention_name>
    <description>cetuximab, irinotecan</description>
    <arm_group_label>EGFR expression</arm_group_label>
    <other_name>PharmDx kit for EGFR staining.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Colorectal adenocarcinoma, Wild KRAS, 18-75 yr&#xD;
&#xD;
          -  Estimated life expectancy of more than 3 months&#xD;
&#xD;
          -  ECOG performance status of 0 to 1 at study entry&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Documented progression during or within 3 months of irinotecan-containing regimens as&#xD;
             a first-line chemotherapy&#xD;
&#xD;
          -  Immunohistochemical evidence of a presence or absence of EGFR expression by PharmDx&#xD;
             Kit&#xD;
&#xD;
          -  Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system (CNS) metastases or prior radiation for CNS metastases.&#xD;
&#xD;
          -  Intestinal obstruction or impending intestinal obstruction due to peritoneal&#xD;
             carcinomatosis&#xD;
&#xD;
          -  Surgery (excluding biopsy for diagnosis) during 4 weeks prior to inclusion in the&#xD;
             study.&#xD;
&#xD;
          -  Evidence of gastrointestinal bleeding&#xD;
&#xD;
          -  Exposure to Cetuximab&#xD;
&#xD;
          -  Prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or&#xD;
             EGFR-targeted treatment&#xD;
&#xD;
          -  KRAS mutant Status&#xD;
&#xD;
          -  Patients with serious toxicity to previous irinotecan-based chemotherapy&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25.</citation>
    <PMID>21706149</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2008</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Tae Won Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

